BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36595982)

  • 21. Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro.
    Kato T; Bilim V; Yuuki K; Naito S; Yamanobe T; Nagaoka A; Yano I; Akaza H; Tomita Y
    Anticancer Res; 2010 Oct; 30(10):4089-96. PubMed ID: 21036724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term protection in bladder cancer following intralesional immunotherapy.
    Reichert DF; Lamm DL
    J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
    Boehm BE; Cornell JE; Wang H; Mukherjee N; Oppenheimer JS; Svatek RS
    J Urol; 2017 Sep; 198(3):503-510. PubMed ID: 28286068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
    Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
    Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
    J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillus Calmette-Guérin cell-wall skeleton enhances the killing activity of cytotoxic lymphocyte-activated human dendritic cells transduced with the prostate-specific antigen gene.
    Fujii R; Iwahashi M; Kikkawa K; Inagaki T; Kohjimoto Y; Ojima T; Mori T; Kuramoto T; Nishizawa S; Azuma I; Yamaue H; Shinka T; Hara I
    BJU Int; 2009 Dec; 104(11):1766-73. PubMed ID: 20063450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.
    Wang Z; So WZ; Loh KY; Lim YK; Mahendran R; Wu QH; Chiong E
    Int J Urol; 2022 Aug; 29(8):807-815. PubMed ID: 35598896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A report of iliac muscle abscess due to Mycobacterium bovis after bacillus Calmette-Guerin therapy for bladder cancer.
    Talluri SK; Marigowda L; Besur S; Talluri J; Forstall GJ
    South Med J; 2010 Apr; 103(4):369-70. PubMed ID: 20224496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
    Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
    Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
    Gellings P; Galeas-Pena M; Morici LA
    Clin Exp Med; 2023 Jun; 23(2):519-527. PubMed ID: 35076789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
    Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
    J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
    Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
    Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial.
    Ochiai T; Sato H; Hayashi R; Asano T; Sato H; Yamamura Y
    Cancer Immunol Immunother; 1983; 14(3):167-71. PubMed ID: 6340825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model.
    Nakamura T; Fukiage M; Suzuki Y; Yano I; Miyazaki J; Nishiyama H; Akaza H; Harashima H
    J Control Release; 2014 Dec; 196():161-7. PubMed ID: 25315488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.